Tag: change

EDMONTON, Alberta, June 30, 2025 (GLOBE NEWSWIRE) -- Capital Power Corporation (TSX: CPX) will release its 2025 second quarter results before the markets open on July 30, 2025. A conference call and webcast to discuss the results will be held the same day at 9:00 a.m. MT (11:00 a.m. ET).

30 June 2025

MONTREAL, June 30, 2025 (GLOBE NEWSWIRE) -- Dorel Industries Inc. (TSX: DII.B, DII.A) is providing a business update on its on-going operations as promised in its first quarter financial results press release issued on May 12, 2025.

The Company is announcing a strategic shift in its operations with a significant reduction in the size of its Home segment which is expected to return the segment to profitability in 2026. These changes will be facilitated by a reduced product line focusing on profitable categories and the elimination of the domestic manufacturing operations based in Cornwall, Ontario.

As described in the first quarter earnings release, Dorel Home initiated a new round of restructuring in the second quarter founded upon the reduction of the size of the organization and its ability to merge the sales, marketing and product development organization into the successful Cosco division. A limited number of high-performing Dorel Home import SKUs will be transferred to the Cosco portfolio, focused on categories and customers driving the highest contribution with the least added complexity.

Cosco has delivered consistent earnings and positive cash flow within the Home segment since 2010, including the period in which it was led by Troy Franks, current CEO of Dorel Home. The organization is built on a market-driven, customer centric approach that delivers innovative products with exceptional consumer value. For over 90 years, Cosco has been a trusted household brand known for reliable performance and quality.

Albion Technology & General VCT PLC

BOSTON, June 30, 2025 (GLOBE NEWSWIRE) -- PathAI, a global leader in artificial intelligence (AI) and digital pathology solutions, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for AISight® Dx*—its digital pathology image management system—for use in primary diagnosis in clinical settings. Building on the initial 510(k) clearance for AISight Dx(Novo) in 2022, this latest milestone underscores the platform’s continuous innovation and PathAI’s commitment to delivering enhanced capabilities as the product evolves.